K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: Some therapeutic implications

Seminars in Dialysis

Volumn 17, Issue 5, 2004, Pages 349-350

  Uribarri, Jaime ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CARBONIC ACID DERIVATIVE; CINACALCET; DOXERCALCIFEROL; LANTHANUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

BONE METABOLISM; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG COST; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; REVIEW; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; TREATMENT PLANNING;

BONE DISEASES, METABOLIC; FEMALE; GUIDELINE ADHERENCE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PROGNOSIS; RENAL DIALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 7044235579     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0894-0959.2004.17354.x     Document Type: Review

References (10)

1. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
2. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607-617, 1998
4. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446-456, 2003
5. Eknoyan G, Levin A, Levin NW: Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(suppl 3):S1-S201, 2003
6. Kim J, Pisoni RL, Danese MD, Satayathum S, Klassen P, Young EW: Achievement of proposed NKF-K/DOQI Bone Metabolism and Disease Guidelines: results from the Dialysis Outcome Practice Patterns Study (DOPPS). J Am Soc Nephrol 14:269-270A, 2003
7. Walters BAJ, Danese MD, Kim JJ, Klassen PS: Patient prevalence within proposed NKF-K/DOQI bone metabolism and disease. J Am Soc Nephrol 14:A473-A474, 2003
8. Urena P, Frazao JM: Calcimimetic agents: review and perspectives. Kidney Int Suppl 85:S91-S96, 2003
9. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004
10. Malluche HH, Mawad H, Koszewski NJ: Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int 62:367-374, 2002